No abstract

Evaluation for JENDL-3.3 has been performed by considering the accumulated feedback information and various benchmark tests of the previous library JENDL-3.2. The major problems of the JENDL-3.2 data were solved by the new library: overestimation of criticality values for thermal fission reactors was improved by the modifications of fission cross sections and fission neutron spectra for 235 U; incorrect energy distributions of secondary neutrons from important heavy nuclides were replaced with statistical model calculations; the inconsistency between elemental and isotopic evaluations was removed for medium-heavy nuclides. Moreover, covariance data were provided for 20 nuclides. The reliability of JENDL-3.3 was investigated by the benchmark analyses on reactor and shielding performances. The results of the analyses indicate that JENDL-3.3 predicts various reactor and shielding characteristics better than JENDL-3.2.

Purpose Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE) of opioids-common analgesics for cancer pain. We investigated the efficacy and safety of a peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), for OIC, specifically in patients with cancer. Patients and Methods This phase III trial consisted of a 2-week, randomized, double-blind, placebo-controlled study (COMPOSE-4) and an open-label, 12-week extension study (COMPOSE-5). In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned on a 1:1 basis to receive once-daily oral naldemedine 0.2 mg or placebo. The primary end point was the proportion of spontaneous bowel movement (SBM) responders (≥ 3 SBMs/week and an increase of ≥ 1 SBM/week from baseline). The primary end point of COMPOSE-5 was safety. Results In COMPOSE-4, 193 eligible patients were randomly assigned to naldemedine (n = 97) or placebo (n = 96). The proportion of SBM responders in COMPOSE-4 was significantly greater with naldemedine than with placebo (71.1% [69 of 97 patients] v 34.4% [33 of 96 patients]; P < .0001). A greater change from baseline was observed with naldemedine than with placebo in the frequency of SBMs/week (5.16 v 1.54; P < .0001), SBMs with complete bowel evacuation/week (2.76 v 0.71; P < .0001), and SBMs without straining/week (3.85 v 1.17; P = .0005). In COMPOSE-4, more patients treated with naldemedine than with placebo reported treatment-emergent AEs (TEAEs) (44.3% [43 of 97 patients] v 26.0% [25 of 96 patients]; P = .01); in COMPOSE-5, 105 (80.2%) of 131 of patients reported TEAEs. Diarrhea was the most frequently reported TEAE in COMPOSE-4 (19.6% [19 of 97 patients] v 7.3% [seven of 96 patients] with naldemedine v placebo) and COMPOSE-5 (18.3% [24 of 131 patients] with naldemedine). Naldemedine was not associated with signs or symptoms of opioid withdrawal and had no notable impact on opioid-mediated analgesia. Conclusion Once-daily oral naldemedine 0.2 mg effectively treated OIC and was generally well tolerated in patients with OIC and cancer.

The fourth version of the Japanese Evaluated Nuclear Data Library has been produced in cooperation with the Japanese Nuclear Data Committee. In the new library, much emphasis is placed on the improvements of fission product and minor actinoid data. Two nuclear model codes were developed in order to evaluate the cross sections of fission products and minor actinoids. Coupled-channel optical model parameters, which can be applied to wide mass and energy regions, were obtained for nuclear model calculations. Thermal cross sections of actinoids were carefully examined by considering experimental data or by the systematics of neighboring nuclei. Most of the fission cross sections were derived from experimental data. A simultaneous evaluation was performed for the fission cross sections of important uranium and plutonium isotopes above 10 keV. New evaluations were performed for the thirty fissionproduct nuclides that had not been contained in the previous library JENDL-3.3. The data for light elements and structural materials were partly reevaluated. Moreover, covariances were estimated mainly for actinoids. The new library was released as JENDL-4.0, and the data can be retrieved from the Web site of the JAEA Nuclear Data Center.